Lebwohl MG, Leonardi C, Menter A, et al. Tildrakizumab efficacy by metabolic syndrome status in psoriasis: post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study. Poster presented at: 28th European Academy of Dermatology
home / authors / lebwohl-mg-leonardi-c-menter-a-et-al-tildrakizumab-efficacy-by-metabolic-syndrome-status-in-psoriasis-post-hoc-analysis-of-3-year-data-from-the-phase-3-resurface-1-study-poster-presented-at-28th-european-academy-of-dermatology
Articles
October 30th 2019
Lebwohl MG, Leonardi C, Menter A, et al. Tildrakizumab efficacy by metabolic syndrome status in psoriasis: post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study. Poster presented at: 28th European Academy of Dermatology Venereology Congress October 9-13, 2019 Madrid, Spain.Gottlieb AB, Leonardi C, Mehta NN, et al. Tildrakizumab efficacy by metabolic syndrome status in psoriasis: post hoc analysis of 3-year data from the phase 3 reSURFACE 2 study. Poster presented at: 28th European Academy of Dermatology and Venereology Congress Madrid, Spain.
Latest Updated Articles
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: July 24th 2024 | Updated: July 27th 2024
Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
Published: July 24th 2024 | Updated: July 27th 2024
Insights from the TROPION-Lung05 Trial at ASCO 2024
Published: July 24th 2024 | Updated: July 27th 2024
Examining Trends, Future Directions in AI and Health Care
Published: July 15th 2024 | Updated: July 27th 2024
No Sex Differences Identified in Aspirin Dosing for Secondary Prevention of ASCVD
Published: July 24th 2024 | Updated: July 27th 2024
Future Directions in the Management of Multiple Myeloma
